Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Erasca, Inc.
Mayo Clinic
Essen Biotech
Memorial Sloan Kettering Cancer Center
Transgene
Memorial Sloan Kettering Cancer Center
Immodulon Therapeutics Ltd
GI Innovation, Inc.
National Cancer Institute (NCI)